Trial Search Results

Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

We hope to determine the maximum tolerated dose of 3 session (i.e., treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size. By increasing radiation dose, we will determine if there is a better outcome without greater toxicity (side effects) for patients.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Radiation: Fractionated Stereotactic Radiosurgery
  • Procedure: Surgical resection of the tumor




Inclusion Criteria:

   - Age 18 years and older with pathologically-proven solid tumor malignancy and 1 to 4
   brain metastases, one of which is 4.2 to 33.5 cm^3.

   - Systemic therapy: Prior cytoxic systemic therapy must be completed ≥ 5 days prior to
   radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic
   therapy to start ≥ 5 days after the completion of SRS.

   - Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
   has not previously been treated with SRS.

   - Ability to understand and the willingness to sign a written informed consent.

   - Life expectancy of ≥ 12 weeks.

Exclusion Criteria:

   - Previously treated with whole brain irradiation

   - Metastatic lesion in question has previously been treated with SRS.

   - > 4 total brain metastases at the time of initial evaluation.

   - Pediatric patients (age < 18), pregnant women, and those who are unable to give
   informed consent.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305